UPDATE: Emergent BioSolutions says FDA has accepted its anthrax vaccine candidate for review


Emergent BioSolutions Inc. EBS, +1.30% said Friday the U.S. Food and Drug Administration has accepted for review its application for approval of its anthrax vaccine. Dubbed AV7909, the vaccine is aimed at people aged 18 through 65 years who have been exposed to anthrax for use along with recommended antibacterial drugs. A decision is expected by April of 2023. “As we progress toward licensure of AV7909, which is designed to follow a two-dose immunization schedule and to elicit a faster immune response, we redouble our efforts to support the government’s overall preparedness and response strategy for large-scale emergencies involving anthrax and other threats to public health,” said Kelly Warfield, Emergent senior vice president for R&D, in a statement. The company has submitted data from a phase 3 clinical trial of the vaccine, as well as from a phase 2 trial. Emergent shares reversed early losses to trade up 2% premarket and have fallen 26% in the year to date, while the s&P500 SPX, +3.06% has fallen 20%.

This article was originally published by Marketwatch.com. Read the original article here.

Previous article: 5 ways the housing market left buyers in the dust — and it’s not over yet
Next articleDeep Dive: These dividend stocks yield at least 5% and have plenty of room to raise payouts


Please enter your comment!
Please enter your name here